Search

Displaying results 11 - 20 of 27 in total
  1. Drug

    Daprodustat

    go.drugbank.com/drugs/DB11682
    ApprovedInvestigational

    [A254167,A254162] Patients with CKD cannot induce erythropoietin (EPO) production in response to hypoxia or anemia. … As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular HIF1α and HIF2α and the induces erythropoiesis.

  2. Drug

    Vadadustat

    go.drugbank.com/drugs/DB12255
    ApprovedInvestigational

    One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in [erythropoietin] (EPO … These transcription factors serve a multitude of roles, including the stimulation of erythropoiesis.

    Categories: Erythropoiesis-Stimulating Agents
  3. Indication

    Anemia caused by Zidovudine

    go.drugbank.com/conditions/DBCOND0112590
    Drugs: Erythropoietin
  4. Indication

    Blood Loss During Surgery

    go.drugbank.com/conditions/DBCOND0060521
    Drugs: Erythropoietin
  5. Drug

    Iron Dextran

    go.drugbank.com/drugs/DB00893
    ApprovedInvestigationalVet approved

    Iron dextran is a dark brown, slightly viscous liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administ...

  6. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hemato...

  7. Drug

    Imetelstat

    go.drugbank.com/drugs/DB14909
    ApprovedInvestigational

    [erythropoietin]), but primary resistance to these agents is frequent - the median response duration is 18 to 24 months, with most responders (70%) relapsing due to loss of sensitivity of erythroid progenitors … [A187838] Standard therapy for anemia in patients with MDS involves the use of erythropoiesis-stimulating agents (e.g.

  8. Drug

    Roxadustat

    go.drugbank.com/drugs/DB04847
    ApprovedInvestigational

    Roxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease. It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transc...

  9. Indication

    Anemia

    go.drugbank.com/conditions/DBCOND0020261
    Drugs: Cyanocobalamin · Daprodustat · Darbepoetin alfa · Epoetin delta · Erythropoietin · Ferrous sulfate anhydrous +10 more
  10. Pathway

    HIF-1 (Hypoxia) Signaling

    smpdb.ca/view/SMP0546631
    Signaling

    Key HIF targets include vascular endothelial growth factor (VEGF) for angiogenesis, erythropoietin (EPO) for red blood cell production, glucose transporters (GLUT1/3) and glycolytic enzymes (e.g., HK2, … Hypoxia triggers stabilization of hypoxia‑inducible factors (HIFs), oxygen‑sensitive transcription factors that orchestrate adaptive responses by inducing genes involved in angiogenesis, erythropoiesis

    Drugs: Aspartic acid · ATP · Proline · Sapropterin · Calcium · Magnesium cation +3 more
    Enzymes: Erythropoietin